Valuation: Novacyt

Market Cap 3.68Cr 4.19Cr 3.47Cr 3.16Cr 5.92Cr 401.49Cr 5.96Cr 42Cr 16Cr 205.11Cr 16Cr 15Cr 659.22Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 3.87Cr 4.41Cr 3.66Cr 3.33Cr 6.24Cr 422.86Cr 6.28Cr 44Cr 17Cr 216.03Cr 17Cr 16Cr 694.29Cr EV / Sales 2026 *
1.27x
EV / Sales 2027 * 1.19x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.40%
1 week+5.30%
Current month+1.00%
1 month-0.39%
3 months+26.43%
6 months+33.25%
Current year+29.67%
1 week 0.48
Extreme 0.4815
0.53
1 month 0.48
Extreme 0.481
0.57
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
30/03/26 Buy

Chief Executive Officer

1,792 0.0025%
30/03/26 Buy

Chairman

15,228 0.0216%
30/03/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
+0.40%+5.30%+7.64%-31.67% 4.19Cr
+0.53%-6.34% - - 118.9Cr
-0.85%-2.10%-33.09%-39.43% 68Cr
+0.18%-1.40%+38.77% - 36Cr
+0.59%+2.69%-43.72%-25.46% 13Cr
-1.60%-7.54%-15.60%+15.72% 7.05Cr
Average -0.12%-0.43%-9.20%-20.21% 41.13Cr
Weighted average by Cap. +0.04%-3.22%-11.66%-32.90%

Financials

2026 *2027 *
Net sales 3.05Cr 3.48Cr 2.88Cr 2.63Cr 4.92Cr 333.41Cr 4.95Cr 34Cr 13Cr 170.33Cr 13Cr 13Cr 547.43Cr 3.49Cr 3.97Cr 3.29Cr 3Cr 5.62Cr 380.77Cr 5.66Cr 39Cr 15Cr 194.53Cr 15Cr 15Cr 625.19Cr
Net income - -
Net Debt 19.56L 22.29L 18.47L 16.84L 31.51L 21Cr 31.74L 2.21Cr 85.62L 11Cr 83.69L 81.88L 35Cr 48.42L 55.18L 45.73L 41.67L 78.01L 53Cr 78.57L 5.47Cr 2.12Cr 27Cr 2.07Cr 2.03Cr 87Cr
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
25/26/25 €0.5070 +0.40% 5,02,109
24/26/24 €0.5050 +1.81% 4,59,464
23/26/23 €0.4960 +1.22% 1,17,753
22/26/22 €0.4900 +0.51% 57,470
21/26/21 €0.4875 +1.25% 86,268

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock